Pyrazole derivatives as potent EGFR inhibitors: synthesis, biological evaluation and in silico and biodistribution study - Supplementary data.docx

  

Fig.SI. In vitro EGFR inhibitory activity of the synthesized compounds (4a-c), n =3, *e and *a for significant difference from erlotinib and compound 4a, respectively at p ≤ 0.01

  

Fig. SII. a) TEM image of compound 4a loaded PEG/PCL nanoparticles, b) Release profile of compound 4a loaded PEG/PCL nanoparticles in buffer solution at pH = 5.5 and 7.4 for 24 h at 37Cº. Data are presented as mean ± SD, (n= 3), c) Overlaid DSC heating thermograms of: (a) pure compound 4a, (b) PEG/PCL, (c) PVA, (e) compound 4a loaded PEG/PCL nanoparticles

  

Fig. SIII. Tumor targeting efficiency; (a) tumor radioactivity uptake, (b) target to non-target ratio (T/NT)